Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2019-10-23 12:50:26
Oslo, Norway, 23 October 2019 Reference is made to the stock exchange announcement on 18 October 2019 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANO) (the "Company") private placement of new shares (the "Private Placement"). The Private Placement is divided into two tranches, as further explained in the stock exchange announcement on 18 October 2019. The share capital increase pertaining to the 5,511,946 new shares, each with a nominal value of NOK 0.20, to be issued in tranche 1 of the Private Placement (the "Tranche 1 Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 23 October 2019, and the Company's share capital has been increased with NOK 1,102,389.20 through the issuance of the Tranche 1 Shares. The Tranche 1 Shares have been delivered to the investors by way of borrowed shares on 22 October 2019 and the Tranche 1 Shares will be delivered to HealthCap VI L.P. to settle the share loan pursuant to the share lending agreement entered into on 16 October 2019. Following registration of the share capital increase related to the Tranche 1 Shares in the NRBE, the Company has an issued share capital of NOK 13,228,672.60, divided into 66,143,363 shares, each with a par value of NOK 0.20. Both the share capital increases pertaining to the Private Placement have now been registered in the NRBE. For further information, please contact: Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to the Continuing Obligations for companies listed on the Oslo Stock Exchange section 3.2.